792122-84-0

Upstream product

• 553-03-7 3,4-dihydro-2(1H)-quinolone 
• 824-94-2 p-methoxybenzyl chloride 

Downstream Products

• 689281-04-7 [1-(4-methoxy-benzyl)-2-oxo-1,2,3,4-tetrahydro-quinolin-3-yl]-acetic acid tert-butyl ester 
• 792122-85-1 1-[(4-methoxyphenyl)methyl]-3-methyl-3,4-dihydroquinolin-2-one 
• 1434503-62-4 1'-(4-methoxybenzyl)-1'H-spiro[cyclopropane-1,3'-quinolin]-2'(4'H)-one 
• 1434503-68-0 3-(2-iodoethy1)-1-[(4-methoxyphenyl)methyl]-3,4-dihydroquinolin-2-one 
• 1434503-81-7 1'-(4-methoxybenzyl)-1'H-spiro[cyclopentane-1,3'-quinolin]-2'(4'H)-one 
• 1434503-65-7 3-(2-chloroethyl)-1-[(4-methoxyphenyl)methyl]-3,4-dihydroquinolin-2-one 
• 1434503-77-1 3-(4-iodobutyl)-1-(4-methoxybenzyl)-3,4-dihydroquinolin-2(1H)-one 
• 92367-59-4 3,3-dimethyl-3,4-dihydroquinolin-2(1H)-one 
• 31883-79-1 3-methyl-3,4-dihydroquinolin-2(1H)-one 
• 61164-71-4 (2-oxo-1,2,3,4-tetrahydro-quinolin-3-yl)-acetic acid 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Provided herein are novel heterocyclic compounds, for example, compounds having Formula I, I-P, II, lI-P, or III. Also provided herein are pharmaceutical compositions comprising the compounds and methods of using the same, for example, in inhibiting aldehyde dehydrogenases and/or for treating various cancers, cancer metastasis, type 2 diabetes, pulmonary arterial hypertension (PAH) or neointimal hyperplasia (NIH).

Photochemical rearrangement of N -chlorolactams: A route to N -heterocycles through concerted ring contraction

We report a novel ring contraction allowing the direct conversion of N-chlorolactams to their corresponding ring-contraction N-heterocycles upon photolysis. Results show that the rearrangement occurs with a variety of N-chlorolactams and that the greater the substitution at the migrating carbon, the greater the yield of product. Importantly, stereochemistry at the migrating carbon is conserved in the product. Rearranged products were isolated as their methyl carbamates in yields varying from 17% to 58%, with the major side product being the recyclable parent lactam.

1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors

A novel series of 1-aryl-3,4-dihydro-1H-quinolin-2-ones have been discovered as potent and selective norepinephrine reuptake inhibitors. Efficient synthetic routes have been developed which allow for the multi-gram preparation of both final targets and ad

TREATMENT OF LEARNING DISABILITIES AND MOTOR SKILLS DISORDER WITH NOREPINEPHRINE REUPTAKE INHIBITORS

Provided are methods and medicaments for treating a learning disability or a Motor Skills Disorder, comprising administering to a patient in need of such treatment an effective amount of a selective norepinephrine reuptake inhibitor.

TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH NOREPINEPHRINE REUPTAKE INHIBITORS

Provided are methods and medicaments for treating a Pervasive Developmental Disorder, comprising administering to a patient in need of such treatment an effective amount of a selective norepinephrine reuptake inhibitor.

TREATMENT OF HOT FLASHES, IMPULSE CONTROL DISORDERS AND PERSONALITY CHANGE DUE TO A GENERAL MEDICAL CONDITION

Selective norepinephrine reuptake inhibitors are useful for the prevention or treatment of hot flashes, vasomotor symptoms, impulse control disorders or personality change due to a general medical condition.

QUINOLONE DERIVATIVES

This invention relates to compounds of formula (I) where -X-, n, R1, R3 and Ar- have the values defined herein, their preparation and use as norepinephrine reuptake inhibitors useful for the treatment of nervous system disorders

Identification of novel potent bicyclic peptide deformylase inhibitors

Screening of our compound collection using Staphylococcus aureus Ni-Peptide deformylase (PDF) afforded a very potent PDF inhibitor with an IC50 in the low nanomolar range but with poor antibacterial activity (MIC). Three-dimensional structural information obtained from Pseudomonas aeruginosa Ni-PDF complexed with the inhibitor suggested the synthesis of a variety of analogues that would maintain high binding affinity while attempting to improve antibacterial activity. Many of the compounds synthesized proved to be excellent PDF-Ni inhibitors and some showed increased antibacterial activity in selected strains.